Company’s 36-month beta value is 0.49.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SONN is 0.61M, and currently, short sellers hold a 0.71% ratio of that floaft. The average trading volume of SONN on October 18, 2024 was 24.99K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
SONN) stock’s latest price update
Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN)’s stock price has gone rise by 20.28 in comparison to its previous close of 5.08, however, the company has experienced a 27.64% increase in its stock price over the last five trading days. globenewswire.com reported 2024-10-17 that PRINCETON, NJ, Oct. 17, 2024 (GLOBE NEWSWIRE) — Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced that it received notice on October 16, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company regained compliance with the bid price requirement in Listing Rule 5550(a)(2) (the “Bid Price Rule”) for continued listing on the Nasdaq Capital Market.
SONN’s Market Performance
SONN’s stock has risen by 27.64% in the past week, with a monthly drop of -23.62% and a quarterly drop of -10.15%. The volatility ratio for the week is 14.77% while the volatility levels for the last 30 days are 12.77% for Sonnet BioTherapeutics Holdings Inc The simple moving average for the past 20 days is 7.74% for SONN’s stock, with a -42.93% simple moving average for the past 200 days.
SONN Trading at 0.54% from the 50-Day Moving Average
After a stumble in the market that brought SONN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.74% of loss for the given period.
Volatility was left at 12.77%, however, over the last 30 days, the volatility rate increased by 14.77%, as shares sank -26.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.20% upper at present.
During the last 5 trading sessions, SONN rose by +27.64%, which changed the moving average for the period of 200-days by -56.61% in comparison to the 20-day moving average, which settled at $5.67. In addition, Sonnet BioTherapeutics Holdings Inc saw -56.11% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for SONN
Current profitability levels for the company are sitting at:
- -219.69 for the present operating margin
- -0.45 for the gross margin
The net margin for Sonnet BioTherapeutics Holdings Inc stands at -142.9. The total capital return value is set at -4.57. Equity return is now at value -264.57, with -100.88 for asset returns.
Based on Sonnet BioTherapeutics Holdings Inc (SONN), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -66.56. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -180.67.
Currently, EBITDA for the company is -18.68 million with net debt to EBITDA at 0.28. When we switch over and look at the enterprise to sales, we see a ratio of 10.19. The receivables turnover for the company is 0.11for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.65.
Conclusion
In a nutshell, Sonnet BioTherapeutics Holdings Inc (SONN) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
